Wall Street analyst estimates for Ovid Therapeutics Inc. (OVID): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infa...
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -14.12 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $12.6M | $208.4M | $1.5M | $392000 | $566000 | $7.3M |
| Cost of Revenue | 0 | $80310 | $141733 | 0 | 0 | 0 | 0 | 0 | 0 | $300000 |
| Gross Profit | -$56512 | -$80310 | -$142000 | 0 | $12.6M | $208.4M | $1.5M | $392000 | $566000 | $7.0M |
| Research & Development | $9.6M | $50.0M | $33.8M | $46.9M | $64.1M | $46.9M | $24.6M | $28.6M | $36.8M | $25.6M |
| Selling, General & Admin | $12.9M | $15.0M | $19.1M | $19.3M | $30.6M | $37.2M | $32.4M | $29.6M | $25.7M | $24.1M |
| Operating Expenses | $22.5M | $65.0M | $52.9M | $61.4M | $94.0M | $84.2M | $57.1M | $59.7M | $62.5M | $49.4M |
| Operating Income | -$22.5M | -$65.0M | -$52.9M | -$61.4M | -$81.4M | $124.2M | -$55.5M | -$59.3M | -$61.9M | -$42.4M |
| EBITDA | -$22.5M | -$64.7M | -$52.8M | -$61.2M | -$81.1M | $124.4M | -$54.2M | -$57.0M | -$57.8M | -$17.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$22.4M | -$64.8M | -$52.0M | -$60.5M | -$81.0M | $124.2M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| Income Tax | -$950 | -$80310 | 0 | 0 | 0 | $1.3M | 0 | 0 | 0 | 0 |
| Net Income | -$22.4M | -$64.8M | -$52.0M | -$60.5M | -$81.0M | $122.8M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| EPS | $-1.14 | $-3.35 | $-2.11 | $-1.51 | $-1.39 | $1.78 | $-0.77 | $-0.74 | $-0.37 | $-0.24 |
| EPS (Diluted) | $-1.14 | $-3.35 | $-2.11 | $-1.51 | $-1.39 | $1.76 | $-0.77 | $-0.74 | $-0.37 | $-0.24 |
| Shares Outstanding (Diluted) | $19.6M | $19.3M | $24.6M | $39.2M | $58.5M | $68.1M | $70.4M | $70.6M | $70.9M | $73.7M |
Price
| Price | $2.68 |
| Market Cap | $500M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLNN · CNTB · CNTX · IFRX · IMA · KLRS · MGNX
Explore sector: Healthcare · Biotechnology
More sections of OVID: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks